002675 logo

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Stock Price

SZSE:002675 Community·CN¥12.7b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

002675 Share Price Performance

CN¥0
-13.52 (-100.00%)
CN¥0
-13.52 (-100.00%)
Price CN¥0

002675 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Excellent balance sheet with proven track record and pays a dividend.

2 Risks
2 Rewards

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Key Details

CN¥2.7b

Revenue

CN¥1.4b

Cost of Revenue

CN¥1.4b

Gross Profit

CN¥1.2b

Other Expenses

CN¥195.6m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 09, 2026
0.24
50.52%
7.14%
11.3%
View Full Analysis

About 002675

Founded
1998
Employees
2583
CEO
Zhi Gang Luo
WebsiteView website
www.dcb-group.com

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. engages in the raw materials, formulations, nuclear medicine, and big health businesses in China and internationally. It operates through API, Formulation, Radio Pharmaceutical, and Others segments. The company offers formulation products, such as powder injections, tablets, capsules, granules, and drop pills for anticoagulation, cardiovascular, anti-tumor, urology, orthopedics, and anti-infection applications. It also provides active pharmaceutical ingredients, including heparin, chondroitin sulfate sodium and calcium, hyaluronic acid, cytochrome C, and collagen, as well as glucosamine hydrochloride, glucosamine sulfate sodium chloride, and glucosamine sulfate potassium chloride; and nadroparin calcium for injection, hydrocortisone sodium succinate for injection, chorionic gonadotrophin for injection, menotropins for injection, ambroxol hydrochloride dispersible tablets, jinjunling capsules, metformin hydrochloride and glibenclamide tablets, clemastine fumarate tablets, and wind-dispelling itch-relieving granules. In addition, the company offers Technetium Methylene Diphosphonate injections; Technetium Tc=labeled tracers; 2-[18F]FDG for early diagnosis of tumors; sodium iodide oral solution; iodine seeds used for internal radiation treatment of various malignant tumors; urea capsules; and jiabaolin glucosamine chondroitin sulfate capsules. Further, it engages in trading; medical technology; medical devices; technical services; biotechnology service promotion; medical research and experimental development; business services; enterprise management, business information, and financial consulting; multimodal transport and transport agency services; capital market services; operation of local platforms for images; and engineering activities. The company exports its products to approximately 40 countries and regions. Yantai Dongcheng Pharmaceutical Group Co.,Ltd. was founded in 1998 and is headquartered in Yantai, China.

Recent 002675 News & Updates

Recent updates

No updates